The Complete Guide to Low-Dose Ketamine Therapy

What Is Low-Dose Ketamine?

Ketamine is a dissociative anesthetic that was first synthesized in 1962 by Calvin Stevens at Parke-Davis Laboratories and approved by the United States Food and Drug Administration (FDA) for use as a general anesthetic in 1970. For over five decades it has been a mainstay of anesthesiology, emergency medicine, and battlefield surgery, valued for its wide therapeutic index and preservation of airway reflexes and hemodynamic stability.

The term "low-dose" or "subanesthetic" ketamine refers to administration at doses substantially below those required for general anesthesia -- typically 0.1 to 0.5 mg/kg intravenously, compared with 1 to 2 mg/kg for anesthetic induction. At these lower doses, ketamine produces distinct neurobiological effects that have proven remarkably effective for conditions that respond poorly to conventional pharmacotherapy, most notably treatment-resistant depression, acute suicidal ideation, and certain chronic pain syndromes.

A Brief History of Ketamine in Psychiatry

The psychiatric potential of ketamine remained largely unexplored until 2000, when Berman and colleagues at Yale University published the first controlled trial demonstrating rapid antidepressant effects of a single intravenous ketamine infusion. The landmark 2006 study by Zarate and colleagues at the National Institute of Mental Health (NIMH) confirmed these findings in a rigorous crossover design, reporting that 71 percent of patients with treatment-resistant depression met response criteria within 24 hours of a single infusion.

These discoveries represented a paradigm shift. For the first time, a pharmacological intervention produced antidepressant effects within hours rather than the four to eight weeks typically required by selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). The finding also challenged the monoamine hypothesis that had dominated psychopharmacology since the 1960s, redirecting attention toward the glutamate system as a critical target for novel antidepressant development.

Ketamine vs. Esketamine: Understanding the Distinction

Ketamine exists as a racemic mixture of two mirror-image enantiomers: S(+)-ketamine (esketamine) and R(-)-ketamine (arketamine). In 2019, the FDA approved intranasal esketamine (Spravato) specifically for treatment-resistant depression, making it the first glutamate-targeting antidepressant to receive regulatory approval. However, the vast majority of clinical experience and published evidence involves racemic intravenous ketamine, and the two formulations differ in pharmacology, administration, cost, and regulatory status. Both represent legitimate clinical options, and the choice between them involves multiple considerations addressed throughout this guide.

How Low-Dose Ketamine Works

The NMDA Receptor and the Disinhibition Hypothesis

Ketamine is classified as a noncompetitive, use-dependent antagonist of the N-methyl-D-aspartate (NMDA) receptor, a subtype of ionotropic glutamate receptor that is widely distributed throughout the central nervous system. Unlike simple receptor blockade, ketamine's mechanism involves a sophisticated cascade of events that ultimately produces its therapeutic effects.

The prevailing explanatory framework is the disinhibition hypothesis, advanced by Moghaddam and colleagues (1997). At subanesthetic doses, ketamine preferentially blocks NMDA receptors on gamma-aminobutyric acid (GABA) interneurons in the prefrontal cortex and hippocampus. These fast-spiking interneurons have higher tonic firing rates than pyramidal neurons, resulting in more frequent NMDA channel openings and greater vulnerability to ketamine's use-dependent blockade. When these inhibitory interneurons are suppressed, the excitatory pyramidal neurons they normally restrain are released from tonic inhibition -- a process termed "disinhibition."

The Glutamate Surge and AMPA Receptor Activation

The disinhibition of pyramidal neurons produces a transient burst of glutamate release in the prefrontal cortex. Because NMDA receptors remain blocked by ketamine, this released glutamate acts primarily on alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. The resulting AMPA-mediated depolarization triggers a downstream signaling cascade that is essential for ketamine's antidepressant effects.

Maeng and colleagues (2008) demonstrated this conclusively by showing that the AMPA receptor antagonist NBQX completely abolished ketamine's antidepressant-like behavioral effects in animal models, while having no effect on the actions of traditional SSRIs. This finding established that ketamine's therapeutic mechanism is fundamentally distinct from monoamine-based antidepressants.

BDNF, mTOR, and Rapid Synaptogenesis

The AMPA receptor activation triggers release of brain-derived neurotrophic factor (BDNF), a key neurotrophin involved in neuronal survival, synaptic plasticity, and learning. BDNF binding to its receptor, tropomyosin receptor kinase B (TrkB), activates the mechanistic target of rapamycin (mTOR) signaling pathway.

Within hours, mTOR activation stimulates rapid synthesis of synaptic proteins and formation of new dendritic spines and synaptic connections in the prefrontal cortex -- a process documented by Li and colleagues (2010) at Yale. This rapid synaptogenesis is believed to reverse the synaptic deficits caused by chronic stress and depression, which are characterized by dendritic atrophy, spine loss, and impaired prefrontal connectivity.

Clinical: The speed of ketamine's neuroplastic effects distinguishes it from all other known antidepressant mechanisms. While SSRIs may eventually promote neuroplasticity through BDNF upregulation over weeks, ketamine achieves measurable synaptogenesis within two to six hours of a single administration.

Additional Mechanisms Under Investigation

Research continues to elucidate additional mechanisms that may contribute to ketamine's therapeutic profile:

• Opioid system interactions: Controversy exists regarding whether endogenous opioid system activation contributes to ketamine's antidepressant effects. A 2018 study by Williams and colleagues found that pretreatment with naltrexone blocked ketamine's antidepressant effects, though subsequent studies have produced mixed results. For a detailed analysis, see our coverage of opioid system interactions.
• Anti-inflammatory effects: Ketamine modulates neuroinflammatory signaling, reducing pro-inflammatory cytokines (IL-6, TNF-alpha) and microglial activation, which may be particularly relevant for the subset of depressed patients with elevated inflammatory biomarkers. See anti-inflammatory mechanisms.
• Default mode network modulation: Neuroimaging studies show that ketamine acutely reduces hyperconnectivity within the default mode network (DMN), a brain network associated with self-referential rumination and depressive cognition.
• Hydroxynorketamine metabolites: The metabolite (2R,6R)-hydroxynorketamine (HNK) may possess independent antidepressant activity through AMPA receptor potentiation without NMDA blockade, though clinical confirmation remains ongoing.

Routes of Administration

Low-dose ketamine can be delivered through multiple routes, each with distinct advantages, limitations, and pharmacokinetic profiles. Understanding these differences is essential for clinicians selecting the optimal approach and for patients evaluating treatment options. For a detailed pharmacokinetic comparison, see the pharmacokinetics overview.

Intravenous (IV) Infusion

Intravenous administration is the most extensively studied route and serves as the reference standard for clinical ketamine research.

Standard protocol: 0.5 mg/kg infused over 40 minutes, as established in the landmark Zarate et al. (2006) trial and replicated across dozens of subsequent randomized controlled trials. For complete protocol details, see IV infusion protocols.

Advantages:

• 100 percent bioavailability with precise dose control
• Largest evidence base supporting efficacy
• Rapid onset of action (effects within minutes of infusion start)
• Ability to titrate rate during infusion based on patient response

Limitations:

• Requires clinic visit with IV access and medical monitoring
• Higher direct cost per session compared with oral or sublingual routes
• Less convenient for maintenance therapy schedules

Intramuscular (IM) Injection

Intramuscular ketamine achieves approximately 93 percent bioavailability with peak plasma levels at 15 to 30 minutes.

Advantages:

• Near-complete bioavailability approaching IV delivery
• Faster administration than IV infusion (no 40-minute infusion required)
• No IV access needed
• Substantial clinical evidence, particularly in emergency and pain settings

Limitations:

• Less precise dose titration compared with IV infusion
• Variable absorption depending on injection site and muscle perfusion
• Injection site discomfort

Sublingual Administration

Sublingual ketamine involves placing a dissolving tablet, troche, or liquid formulation under the tongue, where the drug is absorbed through the sublingual mucosa. Bioavailability is approximately 25 to 30 percent. See sublingual and oral protocols for detailed guidance.

Advantages:

• Noninvasive, no needles or IV access required
• Suitable for at-home use under telemedicine supervision in some clinical models
• Partially bypasses first-pass hepatic metabolism
• Lower cost than IV or IM in many settings

Limitations:

• Bioavailability is variable and substantially lower than parenteral routes
• Patient technique (hold time, avoidance of swallowing) affects absorption
• Bitter taste may reduce adherence
• Less extensive controlled trial evidence compared with IV

Oral Administration

Oral ketamine has the lowest bioavailability of common routes, approximately 16 to 24 percent, due to extensive first-pass hepatic metabolism. Oral dosing produces higher norketamine-to-ketamine ratios, which may have distinct pharmacological implications.

Advantages:

• Simplest route of administration
• Lowest cost per dose
• Convenient for home-based maintenance protocols

Limitations:

• Low and variable bioavailability
• Higher exposure to norketamine relative to parent compound
• Slower onset, with peak effects at 30 to 60 minutes
• Gastrointestinal side effects may be more pronounced

Intranasal Administration

Intranasal delivery bypasses first-pass metabolism via absorption through the nasal mucosa, achieving bioavailability of 25 to 50 percent. The FDA-approved intranasal esketamine (Spravato) uses a standardized device for consistent delivery. For details on the esketamine protocol, see intranasal esketamine.

Advantages:

• Noninvasive administration
• FDA-approved formulation available (esketamine/Spravato)
• Moderate bioavailability with partial bypass of first-pass metabolism
• Standardized dosing device reduces variability

Limitations:

• FDA-approved formulation restricted to certified treatment centers (REMS program)
• Nasal congestion, mucosal pathology, and technique affect absorption
• Significant cost differential for FDA-approved esketamine
• Generic intranasal compounded formulations lack standardized evidence base

Clinical: Route selection should be individualized based on clinical indication, treatment phase (acute vs. maintenance), patient preference, access to clinic-based monitoring, cost considerations, and the quality of evidence supporting each route for the specific condition being treated. IV infusion remains the best-supported option for acute treatment-resistant depression.

What to Expect During Treatment

Before Your First Session

A thorough evaluation before initiating ketamine therapy typically includes:

• Comprehensive psychiatric assessment confirming the diagnosis and documenting prior treatment trials
• Medical history review with attention to cardiovascular disease, uncontrolled hypertension, hepatic impairment, active substance use disorders, and personal or family history of psychotic disorders
• Physical examination and baseline vital signs
• Review of current medications, particularly monoamine oxidase inhibitors (MAOIs), benzodiazepines, and lamotrigine, which may interact with ketamine's effects
• Informed consent process covering expected effects, risks, alternatives, and the off-label nature of racemic ketamine use for psychiatric indications
• Screening for contraindications

During an IV Infusion Session

A typical IV ketamine infusion for depression follows a well-established clinical sequence:

Pre-infusion (15 to 30 minutes): Vital signs are obtained, including blood pressure, heart rate, respiratory rate, and oxygen saturation. An IV line is established, and the patient is positioned comfortably in a reclining chair or bed in a calm, dimly lit environment.

During infusion (40 minutes): The standard dose of 0.5 mg/kg is infused over 40 minutes. Vital signs are monitored at regular intervals, typically every 10 to 15 minutes. Patients commonly begin to notice effects within 10 to 15 minutes, which may include:

• A sense of floating or disconnection from the body (dissociation)
• Perceptual changes such as altered visual or auditory processing
• A dreamlike or contemplative mental state
• Mild dizziness or lightheadedness
• Nausea (typically mild and self-limiting)

Post-infusion monitoring (60 to 120 minutes): After the infusion concludes, patients remain monitored until vital signs normalize and dissociative effects have substantially resolved. Most patients are ready for discharge approximately 60 to 90 minutes after infusion completion. Patients must not drive or operate heavy machinery for the remainder of the day and must arrange transportation home.

Treatment Course Structure

For treatment-resistant depression, most established clinical protocols follow a phased approach:

Acute phase: Six infusions administered over two to three weeks (typically Monday-Wednesday-Friday for two weeks). This schedule is derived from clinical trials and real-world practice data showing that serial infusions produce cumulative benefit.

Assessment: Clinical response is evaluated using standardized rating scales such as the Patient Health Questionnaire-9 (PHQ-9), Montgomery-Asberg Depression Rating Scale (MADRS), or Beck Depression Inventory (BDI). Patients who demonstrate meaningful response proceed to maintenance.

Maintenance phase: Individually titrated infusions at intervals of two to six weeks, adjusted based on clinical response and symptom recurrence. See maintenance infusion protocols for detailed strategies.

Efficacy: What the Evidence Shows

Treatment-Resistant Depression

The evidence base for low-dose ketamine in treatment-resistant depression (TRD) is the most robust of any indication. Key findings from the published literature include:

• Response rates: Across multiple randomized controlled trials and meta-analyses, approximately 60 to 70 percent of patients with TRD achieve meaningful clinical response (defined as 50 percent or greater reduction in depression severity scores) following a series of infusions. This compares favorably with response rates of approximately 10 to 30 percent for switching to another conventional antidepressant after two prior failures.
• Remission rates: Full remission (defined as depression severity scores below clinical threshold) is achieved by approximately 30 to 40 percent of responders with serial infusion protocols.
• Speed of onset: The rapid antidepressant effects are among ketamine's most distinctive features. Significant improvement is typically measurable within two to four hours of a single infusion, with peak effect at 24 hours.
• Duration of effect: A single infusion typically provides antidepressant benefit lasting five to seven days. Serial infusion protocols and maintenance schedules extend the duration of response substantially, with some patients maintaining remission for months to years with periodic booster infusions.

A comprehensive meta-analysis of ketamine for depression published in the American Journal of Psychiatry synthesized data across 36 randomized controlled trials and confirmed large effect sizes for ketamine versus placebo at 24 hours (Hedges' g = 1.0), with sustained but diminishing effects over two weeks.

Suicidal Ideation

Perhaps the most clinically consequential finding is ketamine's rapid reduction of suicidal ideation. Multiple controlled trials have demonstrated significant reductions in suicidal thoughts within hours of administration, often independent of general antidepressant effects. This property has particularly important implications for emergency department and acute psychiatric settings, where rapid stabilization of actively suicidal patients can be lifesaving.

Beyond Depression

While the evidence base is strongest for TRD, accumulating data support ketamine's efficacy across several additional conditions:

• Chronic pain: Low-dose ketamine infusions provide analgesic benefit for chronic pain syndromes, neuropathic pain, complex regional pain syndrome, and fibromyalgia, likely through central sensitization modulation and descending pain pathway effects.
• PTSD: Emerging evidence supports rapid symptom reduction in post-traumatic stress disorder, potentially by disrupting fear memory reconsolidation and reducing amygdala hyperactivity.
• Anxiety disorders: Studies report anxiolytic effects in generalized and social anxiety disorders, though the evidence base is smaller than for depression.
• OCD: Preliminary data suggest benefit in obsessive-compulsive disorder, particularly for patients who have not responded to SSRIs and cognitive-behavioral therapy.
• Bipolar depression: Ketamine shows promise for the depressive phase of bipolar disorder, though careful monitoring for manic switching is required.

Info: The evidence base varies significantly across conditions. While treatment-resistant depression is supported by numerous large, well-designed randomized controlled trials, evidence for conditions such as OCD and PTSD is primarily derived from smaller pilot studies and open-label trials. Patients and clinicians should weigh the strength of available evidence when considering ketamine for conditions beyond TRD.

Safety Profile and Side Effects

Common Side Effects

The most frequently reported adverse effects during and shortly after low-dose ketamine administration are dose-dependent, transient, and self-limiting. For a detailed review, see common side effects.

Dissociation: The most characteristic subjective effect, reported by approximately 60 to 80 percent of patients during IV infusion at standard antidepressant doses. Dissociation typically involves feelings of detachment from the body, altered time perception, and a dreamlike quality to experience. It peaks during or shortly after infusion and resolves within 60 to 90 minutes. Notably, the degree of dissociation has been inconsistently correlated with antidepressant response -- some studies suggest a positive association, while others find no relationship.

Nausea: Reported by approximately 15 to 30 percent of patients. Pre-treatment with ondansetron (4 to 8 mg) or granisetron can mitigate this effect when anticipated.

Hemodynamic changes: Ketamine produces modest, transient elevations in blood pressure and heart rate, typically peaking during infusion and normalizing within 30 to 60 minutes of completion. Standard cardiovascular monitoring protocols include blood pressure and heart rate assessment before, during, and after infusion. Patients with uncontrolled hypertension (resting systolic blood pressure >180 mmHg or diastolic >100 mmHg) are generally excluded from treatment.

Perceptual disturbances: Mild visual distortions, heightened sensory awareness, and altered auditory processing are common during infusion and resolve rapidly.

Dizziness and sedation: Reported frequently but are typically mild at subanesthetic doses.

Serious and Long-Term Safety Considerations

Abuse potential: Ketamine is a Schedule III controlled substance with recognized abuse liability. However, the risk profile of clinic-based, medically supervised subanesthetic administration differs fundamentally from recreational high-dose use. Structured treatment protocols with appropriate patient selection and monitoring substantially mitigate this risk. For a comprehensive analysis, see abuse potential assessment.

Urological toxicity: Chronic, high-dose recreational ketamine use is associated with ulcerative interstitial cystitis (sometimes called "ketamine bladder"), which can produce severe urinary frequency, urgency, and pain. This complication has not been reported at clinical subanesthetic doses used in psychiatric or pain treatment, likely due to the vastly lower cumulative drug exposure. Nevertheless, long-term safety monitoring should include periodic inquiry about lower urinary tract symptoms.

Hepatotoxicity: Elevated liver enzymes have been reported with chronic, high-dose ketamine exposure. Clinical-dose protocols have not been associated with hepatotoxicity, but baseline and periodic liver function monitoring is reasonable for patients on long-term maintenance regimens. See hepatotoxicity risk.

Cognitive effects: Concerns exist regarding potential cognitive effects with repeated ketamine exposure. Available longitudinal data from clinical-dose studies have not identified persistent cognitive impairment, but the evidence base for very long-term administration (beyond two to three years) remains limited.

Warning: Ketamine is contraindicated in patients with uncontrolled hypertension, active psychotic symptoms, unstable aneurysmal vascular disease, and conditions where elevated intracranial pressure would be dangerous. A thorough medical and psychiatric screening should precede any treatment initiation.

Contraindications

Absolute and relative contraindications include:

• Active psychosis or schizophrenia: Ketamine can exacerbate psychotic symptoms through glutamatergic mechanisms
• Uncontrolled hypertension: Ketamine's sympathomimetic effects pose cardiovascular risk
• Unstable cardiovascular disease: Including recent myocardial infarction, unstable angina, or aortic aneurysm
• Active substance use disorders: Particularly involving ketamine, PCP, or other dissociatives
• Elevated intracranial pressure: Though the magnitude of ketamine's effect on ICP in spontaneously breathing patients is debated
• Pregnancy: Limited safety data; see pregnancy and lactation considerations

For comprehensive screening guidance, see contraindications and screening.

Patient Selection: Who Is a Good Candidate?

Appropriate patient selection is one of the most important determinants of treatment success and safety. The ideal candidate for low-dose ketamine therapy typically meets the following criteria:

Clinical Indications

• Documented treatment resistance: For depression, this generally means failure of at least two adequate trials of antidepressant medication at therapeutic doses for adequate durations (typically 6 to 8 weeks each). Comprehensive documentation of prior treatment trials is essential.
• Significant functional impairment: The severity of the condition justifies the risks, costs, and logistical demands of ketamine treatment.
• Realistic expectations: Patients who understand that ketamine is not a cure but rather a tool that can provide rapid relief while other therapeutic interventions (psychotherapy, lifestyle changes, medication optimization) are consolidated.

Medical Suitability

• Stable cardiovascular status with controlled blood pressure
• Adequate hepatic function
• No active substance use disorders
• No active psychotic symptoms or primary psychotic disorders
• No pregnancy or plans for pregnancy during treatment

Psychosocial Factors

• Reliable transportation to and from treatment sessions
• A stable living situation that supports recovery
• Willingness to engage in concurrent psychotherapy
• Adequate support system
• Understanding of and agreement to the informed consent requirements

For detailed selection criteria, see patient selection criteria.

Cost and Access Considerations

Current Cost Landscape

The cost of ketamine therapy varies substantially based on route of administration, geographic location, and clinical setting:

• IV ketamine infusions: Typically $400 to $800 per infusion at specialty clinics, with a standard acute series of six infusions totaling $2,400 to $4,800. Insurance coverage is inconsistent, as IV racemic ketamine for psychiatric indications is off-label.
• Intranasal esketamine (Spravato): The per-session cost is approximately $600 to $900, but is more frequently covered by insurance due to its FDA approval for TRD. Treatment must occur at REMS-certified treatment centers. See our cost-effectiveness analysis for detailed comparisons.
• Oral and sublingual ketamine: Compounded formulations may cost $50 to $200 per month for the medication alone, though prescriber fees, monitoring visits, and telemedicine platform fees add to total cost.

Insurance Coverage

Insurance coverage for ketamine therapy remains a significant barrier for many patients. FDA-approved intranasal esketamine (Spravato) has the broadest insurance coverage but typically requires prior authorization documenting treatment resistance. Off-label IV racemic ketamine is rarely covered by insurance, though some clinics offer financing plans or sliding scale fees.

Finding Qualified Providers

When seeking a ketamine treatment provider, patients should look for:

• Board-certified physicians (psychiatrists, anesthesiologists, or other qualified specialists) with specific training in ketamine administration for psychiatric or pain indications
• Clinics with comprehensive monitoring and assessment protocols
• Providers who perform thorough screening evaluations before initiating treatment
• Integration with ongoing psychiatric care and psychotherapy
• Transparent pricing and evidence-based treatment protocols
• Willingness to share outcome data and clinical protocols

Tip: Patients should be cautious about clinics that guarantee results, do not perform medical screenings, discourage concurrent psychotherapy, or offer excessively low prices that may indicate insufficient monitoring and support. High-quality ketamine therapy requires medical expertise, proper monitoring equipment, and adequate staffing.

The Future of Ketamine Therapy

Research Directions

The ketamine field continues to advance rapidly across several frontiers:

• Biomarker development: Researchers are investigating blood-based biomarkers (BDNF levels, inflammatory markers, metabolomic profiles), neuroimaging signatures, and genetic polymorphisms that may predict individual treatment response, enabling more personalized approaches to patient selection and dose optimization.
• Next-generation glutamatergic agents: Pharmaceutical development is focused on drugs that capture ketamine's rapid antidepressant mechanism while potentially avoiding dissociative effects, abuse liability, or the need for clinical monitoring. Several NMDA receptor modulators and AMPA receptor potentiators are in clinical development.
• Optimized protocols: Ongoing trials are comparing different dosing regimens, infusion durations, and maintenance schedules to identify the most efficient and durable treatment approaches.
• Combination strategies: Research into combination therapy protocols pairing ketamine with psychotherapy, transcranial magnetic stimulation, or specific pharmacological agents aims to enhance and extend treatment response.
• Novel routes and formulations: Subcutaneous injection, extended-release oral formulations, and novel intranasal devices are being developed to improve convenience and consistency.

Evolving Clinical Standards

The practice of ketamine therapy is rapidly professionalizing. Clinical practice guidelines from organizations including the American Psychiatric Association, the American Society of Ketamine Physicians, Psychotherapists and Practitioners, and various international psychiatric societies continue to refine recommendations for patient selection, dosing, monitoring, and ethical practice standards.

Conclusion

Low-dose ketamine represents one of the most significant advances in psychiatric pharmacology in decades. Its unique glutamatergic mechanism, rapid onset of action, and efficacy in treatment-resistant populations address critical unmet needs in mental health care. While important questions remain regarding optimal long-term treatment strategies, patient selection biomarkers, and the development of next-generation therapeutics, the current evidence firmly establishes ketamine as a valuable and scientifically grounded treatment option for appropriately selected patients.

The decision to pursue ketamine therapy should be made in close collaboration with qualified healthcare providers who can perform thorough evaluations, deliver treatment with proper monitoring, and integrate ketamine into a comprehensive treatment plan that includes psychotherapy and ongoing psychiatric care.

References

• Berman RM et al. Antidepressant effects of ketamine in depressed patients. Biological Psychiatry, 2000 -- First controlled trial demonstrating rapid antidepressant effects of a single IV ketamine infusion
• Zarate CA et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Archives of General Psychiatry, 2006 -- Landmark NIMH crossover trial establishing the 0.5 mg/kg IV paradigm for TRD
• Moghaddam B et al. Activation of glutamatergic neurotransmission by ketamine. Journal of Neuroscience, 1997 -- Foundational study demonstrating ketamine-induced glutamate surge via disinhibition
• Li N et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 2010 -- Demonstrated rapid synaptogenesis in prefrontal cortex following ketamine administration
• Maeng S et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of AMPA receptors. Biological Psychiatry, 2008 -- Established essential role of AMPA receptor activation in ketamine's antidepressant mechanism
• Wilkinson ST et al. The effect of a single dose of intravenous ketamine on suicidal ideation. American Journal of Psychiatry, 2018 -- Systematic review and individual patient data meta-analysis of antisuicidal effects
• FDA Spravato (esketamine) prescribing information. U.S. Food and Drug Administration, 2019 -- Official prescribing information for the FDA-approved intranasal esketamine formulation
• Ketamine for Treatment-Resistant Depression. National Institute of Mental Health (NIMH) -- NIMH overview of ketamine as an emerging treatment for depression
• McIntyre RS et al. Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression. American Journal of Psychiatry, 2021 -- Comprehensive synthesis of randomized controlled trial evidence across formulations
• World Health Organization. Model List of Essential Medicines, 23rd Edition, 2023 -- WHO recognition of ketamine as an essential medicine
• Ketamine. Mayo Clinic Drug Information -- Patient-oriented overview of ketamine indications and safety